Comprehensive analysis reveals an arachidonic acid metabolism-related gene signature in patients with pancreatic ductal adenocarcinoma

被引:0
作者
ZHU, H. U. I. L. I. [1 ,2 ]
XIAO, L. I. N. A. [1 ,2 ]
YIN, X. I. A. [1 ,2 ]
XIANG, S. H. I. B. I. N. G. [1 ,2 ]
WANG, C. H. U. N. H. U., I [3 ]
机构
[1] Sichuan Univ, West China Sch Publ Hlth, Dept Gastroenterol, Chengdu 610041, Peoples R China
[2] Sichuan Univ, West China Hosp 4, Dept Gastroenterol, Chengdu 610041, Peoples R China
[3] Sichuan Univ, West China Hosp, Dept Gastroenterol, Chengdu 610041, Peoples R China
关键词
Arachidonic acid metabolism; Gene signature; Pancreatic ductal adenocarcinoma; Overall survival; Immune status; EPOXYEICOSATRIENOIC ACIDS; EXPRESSION; CYCLOOXYGENASE-2; EICOSANOIDS; PATHWAY; 5-LIPOXYGENASE; PROGRESSION; PROMOTES; DELETION; CLONING;
D O I
10.32604/biocell.2022.020389
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Pancreatic ductal adenocarcinoma (PDAC) is highly heterogeneous, making its prognosis prediction difficult. The arachidonic acid (AA) cascade is involved in carcinogenesis. Therefore, the metabolic enzymes of the AA cascade consist of lipoxygenases (LOXs), phospholipase A2s (PLA2s), and cyclooxygenases (COXs) along with their metabolic products, including leukotrienes. Nevertheless, the prognostic potential of AA metabolism-associated PDAC has not been explored. Herein, the mRNA expression patterns and the matching clinical information of individuals with PDAC were abstracted from online data resources. We employed the LASSO Cox regression model to develop a multigene clinical signature in the TCGA queue. The GEO queue and the ICGC queue were employed as the validation queue. There was differential expression of a significant number of AA metabolism-associated genes (56.8%) between PDAC and neighboring nonmalignant tissues in the TCGA queue. Univariate Cox regression demonstrated that 13 of the differentially expressed genes (DEGs) were linked to overall survival (OS) (p < 0.05). A 6-gene clinical signature was developed for stratifying the PDAC patients into two risk groups, with the high-risk group patients exhibiting remarkably lower OS than the low-risk group patients (p < 0.001 in the TCGA data set and the ICGC queue, and p = 0.001 in the GEO data set). The multivariate Cox data revealed the risk score as an independent OS predictor (HR > 1, p < 0.01). The receiver operating characteristic (ROC) curve verified the predictive potential of our signature. The expression and alteration of the six genes in PDAC were also validated using online databases. Functional analyses demonstrated that immune-linked cascades were enriched, and the immune status was remarkably different between the high- and low-risk groups. In summary, an AA metabolism-associated clinical gene signature can be applied for prognostic estimation in PDAC.
引用
收藏
页码:2241 / 2256
页数:16
相关论文
共 50 条
  • [21] Identification of an Immune-Related Signature for Predicting Prognosis in Patients With Pancreatic Ductal Adenocarcinoma
    Wang, Weijia
    Yan, Liang
    Guan, Xiaoya
    Dong, Bin
    Zhao, Min
    Wu, Jianhui
    Tian, Xiuyun
    Hao, Chunyi
    FRONTIERS IN ONCOLOGY, 2021, 10
  • [22] Exosome and lipid metabolism-related genes in pancreatic adenocarcinoma: a prognosis analysis
    Wu, Jia
    Li, Yajun
    Nabi, Ghulam
    Huang, Xin
    Zhang, Xu
    Wang, Yuanzhen
    Huang, Liya
    AGING-US, 2023, 15 (20): : 11331 - 11368
  • [23] A multi-gene signature predicts outcome in patients with pancreatic ductal adenocarcinoma
    Syed Haider
    Jun Wang
    Ai Nagano
    Ami Desai
    Prabhu Arumugam
    Laurent Dumartin
    Jude Fitzgibbon
    Thorsten Hagemann
    John F Marshall
    Hemant M Kocher
    Tatjana Crnogorac-Jurcevic
    Aldo Scarpa
    Nicholas R Lemoine
    Claude Chelala
    Genome Medicine, 6
  • [24] A multi-gene signature predicts outcome in patients with pancreatic ductal adenocarcinoma
    Haider, Syed
    Wang, Jun
    Nagano, Ai
    Desai, Ami
    Arumugam, Prabhu
    Dumartin, Laurent
    Fitzgibbon, Jude
    Hagemann, Thorsten
    Marshall, John F.
    Kocher, Hemant M.
    Crnogorac-Jurcevic, Tatjana
    Scarpa, Aldo
    Lemoine, Nicholas R.
    Chelala, Claude
    GENOME MEDICINE, 2014, 6
  • [25] Development and validation of a novel lipid metabolism-related gene prognostic signature and candidate drugs for patients with bladder cancer
    Ke Zhu
    Liu Xiaoqiang
    Wen Deng
    Wang, Gongxian
    Bin Fu
    LIPIDS IN HEALTH AND DISEASE, 2021, 20 (01)
  • [26] Prognostic Implication of a Novel Metabolism-Related Gene Signature in Hepatocellular Carcinoma
    Yuan, Chaoyan
    Yuan, Mengqin
    Chen, Mingqian
    Ouyang, Jinhua
    Tan, Wei
    Dai, Fangfang
    Yang, Dongyong
    Liu, Shiyi
    Zheng, Yajing
    Zhou, Chenliang
    Cheng, Yanxiang
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [27] A Novel Signature of Lipid Metabolism-Related Gene Predicts Prognosis and Response to Immunotherapy in Lung Adenocarcinoma
    Zhang, Kai
    Qian, Ying
    Quan, Xiaowei
    Zhu, Tengteng
    Qian, Biyun
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2022, 9
  • [28] Drug metabolism-related eight-gene signature can predict the prognosis of gastric adenocarcinoma
    Yin, Hong-Mei
    He, Qiong
    Chen, Jia
    Li, Zhen
    Yang, Wanli
    Hu, Xiaobo
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2021, 35 (12)
  • [29] Establishing and validating an ADCP-related prognostic signature in pancreatic ductal adenocarcinoma
    Zhang, Deyu
    Cui, Fang
    Peng, Lisi
    Wang, Meiqi
    Yang, Xiaoli
    Xia, Chuanchao
    Li, Keliang
    Yin, Hua
    Zhang, Yang
    Yu, Qihong
    Jin, Zhendong
    Huang, Haojie
    AGING-US, 2022, 14 (15): : 6299 - 6315
  • [30] Development of a lipid metabolism-related gene model to predict prognosis in patients with pancreatic cancer
    Xu, Hong
    Sun, Jian
    Zhou, Ling
    Du, Qian-Cheng
    Zhu, Hui-Ying
    Chen, Yang
    Wang, Xin-Yu
    WORLD JOURNAL OF CLINICAL CASES, 2021, 9 (35) : 10884 - 10898